Inform your doctor of any other medical conditions, allergies, pregnancy, or breast-feeding
doi: 10.1080/15548627.2021.1962681 32
7 hours | Primary site of action: cytoskeleton, actin polymerization | Key receptors: G-actin, ILK-PI3K-Akt | Research focus: tissue repair, cell migration | Endogenous: yes (Thymosin Beta-4 fragment) | Gene modulation: moderately documented What Safety Aspects Are Known from Research
Sn phm ang c nhiu khch hng tin tng v s dng lu di trong sut qu trnh h tr cc vn v da nh thm nm, tn nhang
Sushma S, Dasarathy S, Tandon RK, Jain S, Gupta S, Bhist MS
Treatment of Diabetes Learning Objectives By the end of this session you should be able to: Define the goals of therapy for type 1 and 2 diabetes in accordance with the American Diabetes Association Clinical Practice Guidelines 2020 & 2021, including the recently updated indications for: Metformin GLP-1 receptor agonists SGLT-2 inhibitors List the categories of pharmacologic agents used in the management of patients with type 1 and 2 diabetes Explain the following for each drug category: mechanisms of action indications contraindications potential side effects major advantages /disadvantages Identify the drug category that individual diabetic medications belong to based upon their non-proprietary names (e.g
.webp)
